Work

RE: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

Year: 2026

Type: letter

Source: JNCI Journal of the National Cancer Institute

DOI: 10.1093/jnci/djag212

Authors: Sheng Yu, Xiushen Wang, Hong Ge

Institutions: Zhengzhou University, Henan Cancer Hospital

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7166737024

Cites: 6

Cited by:

Related to: